書誌事項
- タイトル別名
-
- Therapeutic Potential of Sparfloxacin for Preventing Mycobacterial Infections.
この論文をさがす
抄録
We studied the therapeutic potential of utilizing sparfloxacin (SPFX), a newly developed quinolone, to prevent various mycobacterial infections. The in vitro activity of SPFX as a preventive agent for various mycobacteria was determined using the actual countmethod on Ogawa egg medium. The minimal inhibitory concentrations (MICs) of SPFXwere as follows: of loxacin-sensitive M. tuberculosis, 0.16-0332μEg/ml; ofloxacin- resistant M. tuberculosis, 0.63-2.5μEg/ml; M. avium; 0.63-10μEg/ml (MICs were equalor less than 1.25μEg/ml in seven out of 11 strains); M. intracellulare, 2.5-10μEg/ml (MICswere equal or more than 10μ/ml in 17 out of 23 strains); M. kansasii, ≥0.08μg/ml; M. chelonae subsp. abscessus, 1.25μg/ml; M. chelonaesubsp. chelonae, 0.63μg/ml; M. scrofulaceum, μg/ml; M. nonchromogenicum, 1.25μg/ml; M. xenopi, ≥0.08μ/ml; M. gordonae, ≥0.08μg/ml. The average serumconcentrations of SPFX during the period of multiple oral administration (200 mg once aday) were 0.35±0.16μg/ml before administration, 0.67±0.32μg/ml after one hour, 1.13±0.21μEg/ml after two hours, 1.27±0.32μg/ml after four hours and 1.31±0.34μg/ml aftersix hours. These results indicate that SPFX has a strong therapeutic potential to preventinfections due to M. tuberculosis, M. kansasii, M. fortuitum, M. chelonae subsp. chelonae, M. scrofulaceum, M.xenopi and M. gordonae. Moreover, it may be expected to be apromising agent against infections due to ofloxacin-resistant M. tuberculosis, M. aviumand M. nonchromogenicum
収録刊行物
-
- 結核
-
結核 69 (5), 351-356, 1994
一般社団法人 日本結核病学会